About senti biosciences inc - SNTI
Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.
SNTI At a Glance
Senti Biosciences, Inc.
2 Corporate Drive
South San Francisco, California 94080
| Phone | 1-650-239-2030 | Revenue | 22.00K | |
| Industry | Biotechnology | Net Income | -61,438,000.00 | |
| Sector | Health Technology | Employees | 39 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SNTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,062.851 |
| Price to Book Ratio | 5.746 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.597 |
| Enterprise Value to Sales | 1,629.715 |
| Total Debt to Enterprise Value | 0.806 |
SNTI Efficiency
| Revenue/Employee | 564.103 |
| Income Per Employee | -1,575,333.333 |
| Receivables Turnover | 0.014 |
| Total Asset Turnover | 0.00 |
SNTI Liquidity
| Current Ratio | 1.666 |
| Quick Ratio | 1.666 |
| Cash Ratio | 1.175 |
SNTI Profitability
| Gross Margin | -16,431.818 |
| Operating Margin | -289,668.182 |
| Pretax Margin | -279,263.636 |
| Net Margin | -279,263.636 |
| Return on Assets | -82.432 |
| Return on Equity | -218.082 |
| Return on Total Capital | -178.184 |
| Return on Invested Capital | -112.942 |
SNTI Capital Structure
| Total Debt to Total Equity | 516.926 |
| Total Debt to Total Capital | 83.791 |
| Total Debt to Total Assets | 56.402 |
| Long-Term Debt to Equity | 421.56 |
| Long-Term Debt to Total Capital | 68.332 |